April 22nd 2024
Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA Accepts BLA for N-803 in BCG-Unresponsive NMIBC Carcinoma In Situ
July 29th 2022The FDA has accepted the biologics license application for N-803 as a treatment for patients with Bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ with or without Ta or T1 disease.
Read More
ADC/ICI Combo Effective in BCG-Unresponsive NMIBC
July 28th 2022Results from a phase 3 study of pembrolizumab and nadofaragene firadenovec in patients with BCG-unresponsive non–muscle invasive bladder cancer suggests that immune checkpoint inhibitors have synergy with antibody drug conjugates.
Read More
Early Efficacy Shown With Gemcitabine/Cabazitaxel/Pembrolizumab in NMIUC
July 24th 2022In an interview with Targeted Oncology, Vignesh Packiam, MD, discussed the research of gemcitabine plus cabazitaxel and pembrolizumab in patients with non-muscle invasive urothelial carcinoma who are unresponsive to docetaxel.
Read More
Success Shown With Biomarker-Informed Treatment in Upper Tract Urothelial Cancer
July 13th 2022In an interview with Targeted Oncology, Matthew T. Campbell, MD, examined the positive phase 1 study results of infigratinib for the treatment of patients with localized upper tract urothelial cancer.
Read More
CG0070 Provides Durable Responses in Certain Patients with Non-Muscle Invasive Bladder Cancer
June 21st 2022In an interview with Targeted Oncology, Roger Li, MD, discussed the use of the CG0070 in combination with pembrolizumab and nivolumab for patients with non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin.
Read More
BLA Submitted to the FDA for N-803 Plus BCG in BCG-Unresponsive Bladder Cancer
May 25th 2022A biologics license application has been submitted to the FDA for N-803 plus Bacillus Calmette-Guérin as treatment for patients with BCG-unresponsive non-muscle invasive bladder cancer in situ with or without Ta or T1 disease.
Read More
More Analyses Explore Benefit of Frontline Maintenance Avelumab Plus BSC in Advanced UC
May 19th 2022In an interview with Targeted Oncology, Joaquim Bellmunt, MD, PhD, discussed the long-term overall survival data for first-line maintenance avelumab in mUC presented at the AUA 2022 Annual Meeting and a sub-analysis of the JAVELIN Bladder 100 trial being read out at the upcoming 2022 ASCO Annual Meeting.
Read More
Mitomycin Gel Maintains QOL in Patients With Low Grade Non-Muscle Invasive Bladder Cancer
May 16th 2022Health-related quality-of-life outcomes were maintained among patients with low grade non-muscle invasive bladder cancer who were treated with UGN-102, a chemoablative reverse thermal gel as a primary approach in the single-arm phase 2b Optima II trial.
Read More
Infigratinib Demonstrates Activity and Tolerability of FGFR Inhibition in Urothelial Carcinoma
May 16th 2022Interim results from a biomarker-informed preoperative study of infigratinib demonstrated substantial activity and tolerability in patients with localized upper tract urothelial carcinoma, according to findings of a phase 1b trial.
Read More
Results of CG0070 Combined With Pembrolizumab in BCG-Unresponsive NMIBC
May 16th 2022Roger Li, MD, shares the results of the phase 2 CORE1 clinical trial, which evaluated CG0070 in combination with pembrolizumab for the treatment of patients with Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer.
Watch